ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  mesna
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 14 and over
Trial IDs: 2009-0471, NCI-2014-02655, NCT01740557
Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
Combination Chemotherapy with or without Rituximab, Imatinib Mesylate, or Dasatinib in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0598, NCI-2011-00861, NCT01319981
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0030, NCI-2011-02941, NCT01424982
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 19
Trial IDs: NB2012, NCI-2013-00034, NCT01857934
Paclitaxel, Ifosfamide and Cisplatin or Bleomycin Sulfate, Etoposide and Cisplatin in Treating Patients with Previously Untreated Intermediate- or Poor-Risk Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-074, NCI-2013-01158, NCT01873326
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0367, NCI-2014-01356, NCT02106988
Chemotherapy before and after Donor Bone Marrow Transplant in Treating Younger Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 25 years
Trial IDs: J13161, NCI-2014-01899, CIR00009809, NA_00091665, NCT02120157
Donor Bone Marrow Transplant Followed by Chemotherapy in Treating Patients with Relapsed or Refractory Severe Aplastic Anemia or Other Bone Marrow Failure Syndromes
Status: Active
Phase: Phase II
Type: Treatment
Age: 73 and under
Trial IDs: J1424, NCI-2014-02148, CIR00006537, CIR00011746, NCT02224872
Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: SJRET6, NCI-2013-00409, NCT01783535
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients with Newly Diagnosed Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to less than 65
Trial IDs: 2014-0559, NCI-2015-00960, NCT02427620
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 29 and under
Trial IDs: 2015LS108, NCI-2015-02023, MT2015-25, NCT02605421
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients with Sarcoma Receiving Chemotherapy
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 65
Trial IDs: 2015-0587, NCI-2016-00801, NCT02732015
Partial Liver Transplant before Bone Marrow Transplant in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 to 65
Trial IDs: j15171, NCI-2016-00821, CRMS-62535, IRB00080373, NCT02702960
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Status: Active
Phase: Phase II
Type: Treatment
Age: 15 to 70
Trial IDs: 15-MMUD, NCI-2016-01455, NCT02793544
Nonmyeloablative Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: UPCI 13-131, NCI-2014-02371, NCT02167958
Surgery and Combination Chemotherapy in Treating Younger Patients with Non-metastatic Standard-Risk Medulloblastoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 3 to 18
Trial IDs: J1403, NCI-2014-01870, CIR00004694, NA_00091840, NCT02212574
Donor TCR Alpha-Beta and CD19-Depleted Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphomas
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: UW14113, NCI-2015-02269, 2015-0996, NCT02652468
Start Over